AAAAAA
Results: 251-275/568
Authors:
MULTHOFF G
BOTZLER C
ALLENBACHER A
ISSELS R
Citation: G. Multhoff et al., EFFECTS OF IFOSFAMIDE ON IMMUNOCOMPETENT EFFECTOR-CELLS, Cancer immunology and immunotherapy, 42(4), 1996, pp. 251-254
Authors:
GOTO S
SAKAI S
KERA J
SUMA Y
SOMA GI
TAKEUCHI S
Citation: S. Goto et al., INTRADERMAL ADMINISTRATION OF LIPOPOLYSACCHARIDE IN TREATMENT OF HUMAN CANCER, Cancer immunology and immunotherapy, 42(4), 1996, pp. 255-261
Authors:
BRUSERUD O
PAWELEC G
Citation: O. Bruserud et G. Pawelec, HUMAN T-LYMPHOCYTE ACTIVATION IN THE PRESENCE OF ACUTE MYELOGENOUS LEUKEMIA BLASTS - STUDIES OF NORMAL POLYCLONAL T-CELLS AND T-LYMPHOCYTE CLONES DERIVED EARLY AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION, Cancer immunology and immunotherapy, 42(3), 1996, pp. 133-140
Authors:
WEINER LM
ALPAUGH RK
AMOROSO AR
ADAMS GP
RING DB
BARTH MW
Citation: Lm. Weiner et al., HUMAN NEUTROPHIL INTERACTIONS OF A BISPECIFIC MONOCLONAL-ANTIBODY TARGETING TUMOR AND HUMAN FC-GAMMA-RIII, Cancer immunology and immunotherapy, 42(3), 1996, pp. 141-150
Authors:
EVANS C
BAUER S
GRUBERT T
BRUCKER C
BAUR S
HEEG K
WAGNER H
LIPFORD GB
Citation: C. Evans et al., HLA-A2-RESTRICTED PERIPHERAL-BLOOD CYTOLYTIC T-LYMPHOCYTE RESPONSE TOHPV TYPE-16 PROTEINS E6 AND E7 FROM PATIENTS WITH NEOPLASTIC CERVICALLESIONS, Cancer immunology and immunotherapy, 42(3), 1996, pp. 151-160
Authors:
LAMOTTE RN
RUBIN MA
BARR E
LEIDEN JM
BLUESTONE JA
MOKYR MB
Citation: Rn. Lamotte et al., THERAPEUTIC EFFECTIVENESS OF THE IMMUNITY ELICITED BY P815 TUMOR-CELLS ENGINEERED TO EXPRESS THE B7-2 COSTIMULATORY MOLECULE, Cancer immunology and immunotherapy, 42(3), 1996, pp. 161-169
Authors:
FACCHETTI P
PRIGIONE I
GHIOTTO F
TASSO P
GARAVENTA A
PISTOIA V
Citation: P. Facchetti et al., FUNCTIONAL AND MOLECULAR CHARACTERIZATION OF TUMOR-INFILTRATING LYMPHOCYTES AND CLONES THEREOF FROM A MAJOR-HISTOCOMPATIBILITY-COMPLEX-NEGATIVE HUMAN TUMOR - NEUROBLASTOMA, Cancer immunology and immunotherapy, 42(3), 1996, pp. 170-178
Authors:
TAYLOR P
GERDER M
MOROS Z
FELDMANN M
Citation: P. Taylor et al., HUMORAL AND CELLULAR-RESPONSES RAISED AGAINST THE HUMAN HER2 ONCOPROTEIN ARE CROSS-REACTIVE WITH THE HOMOLOGOUS PRODUCT OF THE NEU PROTOONCOGENE, BUT DO NOT PROTECT RATS AGAINST B104 TUMORS EXPRESSING MUTATED NEU, Cancer immunology and immunotherapy, 42(3), 1996, pp. 179-184
Authors:
BJORGE L
JENSEN TS
MATRE R
Citation: L. Bjorge et al., CHARACTERIZATION OF THE COMPLEMENT-REGULATORY PROTEINS DECAY-ACCELERATING FACTOR (DAF,CD55) AND MEMBRANE COFACTOR PROTEIN (MCP,CD46) ON A HUMAN COLONIC ADENOCARCINOMA CELL-LINE, Cancer immunology and immunotherapy, 42(3), 1996, pp. 185-192
Authors:
PAWELEC G
REHBEIN A
SCHLOTZ E
DASILVA P
Citation: G. Pawelec et al., CELLULAR IMMUNE-RESPONSES TO AUTOLOGOUS CHRONIC MYELOGENOUS LEUKEMIA-CELLS IN-VITRO, Cancer immunology and immunotherapy, 42(3), 1996, pp. 193-199
Authors:
MUNKER R
STOTZER O
DARSOW M
CLASSEN S
LEBEAU A
WILMANNS W
Citation: R. Munker et al., AUTOANTIBODIES AGAINST P53 ARE NOT INCREASED IN HUMAN ASCITES AND PLEURAL EFFUSIONS, Cancer immunology and immunotherapy, 42(3), 1996, pp. 200-201
Authors:
GRAHAM RA
BURCHELL JM
TAYLORPAPADIMITRIOU J
Citation: Ra. Graham et al., THE POLYMORPHIC EPITHELIAL MUCIN - POTENTIAL AS AN IMMUNOGEN FOR A CANCER VACCINE, Cancer immunology and immunotherapy, 42(2), 1996, pp. 71-80
Authors:
FAGERBERG J
RAGNHAMMAR P
LILJEFORS M
HJELM AL
MELLSTEDT H
FRODIN JE
Citation: J. Fagerberg et al., HUMORAL ANTIIDIOTYPIC AND ANTI-ANTI-IDIOTYPIC IMMUNE-RESPONSE IN CANCER-PATIENTS TREATED WITH MONOCLONAL-ANTIBODY 17-1A, Cancer immunology and immunotherapy, 42(2), 1996, pp. 81-87
Authors:
PANCOOK JD
BECKER JC
GILLIES SD
REISFEID RA
Citation: Jd. Pancook et al., ERADICATION OF ESTABLISHED HEPATIC HUMAN NEUROBLASTOMA METASTASES IN MICE WITH SEVERE COMBINED IMMUNODEFICIENCY BY ANTIBODY-TARGETED INTERLEUKIN-2, Cancer immunology and immunotherapy, 42(2), 1996, pp. 88-92
Authors:
ELSASSERBEILE U
WETTERAUER U
SCHULTZESEEMANN W
GALLATI H
MONTING JS
VONKLEIST S
Citation: U. Elsasserbeile et al., ANALYSIS OF THE IMMUNE REACTIVITY OF INFILTRATING AND PERIPHERAL LYMPHOCYTES FROM PATIENTS WITH RENAL-CELL CARCINOMA BY MEASURING CYTOKINE SECRETION, Cancer immunology and immunotherapy, 42(2), 1996, pp. 93-98
Authors:
PANELLI MC
WANG E
SHEN SX
SCHLUTER SF
BERNSTEIN RM
HERSH EM
STOPECK A
GANGAVALLI R
BARBER J
JOLLY D
AKPORIAYE ET
Citation: Mc. Panelli et al., INTERFERON GAMMA(IFN-GAMMA) GENE-TRANSFER OF AN EMT6 TUMOR THAT IS POORLY RESPONSIVE TO IFN-GAMMA STIMULATION - INCREASE IN TUMOR IMMUNOGENICITY IS ACCOMPANIED BY INDUCTION OF A MOUSE CLASS-II TRANSACTIVATOR AND CLASS-II MHC, Cancer immunology and immunotherapy, 42(2), 1996, pp. 99-107
Authors:
SENEKOWITSCHSCHMIDTKE R
STEINER K
HAUNSCHILD J
MOLLENSTADT S
TRUCKENBRODT R
Citation: R. Senekowitschschmidtke et al., IN-VIVO EVALUATION OF EPIDERMAL GROWTH-FACTOR (EGF) RECEPTOR DENSITY ON HUMAN TUMOR XENOGRAFTS USING RADIOLABELED EGF AND ANTI-(EGF RECEPTOR) MAB-425, Cancer immunology and immunotherapy, 42(2), 1996, pp. 108-114
Authors:
ROSENBLUM MG
CHEUNG L
KIM SK
MUJOO K
DONATO NJ
MURRAY JL
Citation: Mg. Rosenblum et al., CELLULAR-RESISTANCE TO THE ANTIMELANOMA IMMUNOTOXIN ZME-GELONIN AND STRATEGIES TO TARGET RESISTANT CELLS, Cancer immunology and immunotherapy, 42(2), 1996, pp. 115-121
Authors:
ZISSEL G
AULITZKY WE
LORENZ J
HUBER C
MULLERQUERNHEIM J
Citation: G. Zissel et al., INDUCTION OF ACCESSORY CELL-FUNCTION OF HUMAN ALVEOLAR MACROPHAGES BYINHALATION OF HUMAN NATURAL INTERLEUKIN-2, Cancer immunology and immunotherapy, 42(2), 1996, pp. 122-126
Authors:
HIMOTO T
WATANABE S
NISHIOKA M
MAEBA T
TANAKA S
SAITO M
Citation: T. Himoto et al., COMBINATION IMMUNOTHERAPY WITH OK-432, RECOMBINANT GRANULOCYTE-COLONY-STIMULATING FACTOR AND RECOMBINANT INTERLEUKIN-2 FOR HUMAN HEPATOCELLULAR-CARCINOMA, Cancer immunology and immunotherapy, 42(2), 1996, pp. 127-131
Authors:
PELLEGRINI P
BERGHELLA AM
DELBEATO T
CICIA S
ADORNO D
CASCIANI CU
Citation: P. Pellegrini et al., DISREGULATION IN TH1 AND TH2 SUBSETS OF CD4-CELLS IN PERIPHERAL-BLOODOF COLORECTAL-CANCER PATIENTS AND INVOLVEMENT IN CANCER ESTABLISHMENTAND PROGRESSION( T), Cancer immunology and immunotherapy, 42(1), 1996, pp. 1-8
Authors:
SAHIN U
KRAFTBAUER S
OHNESORGE S
PFREUNDSCHUH M
RENNER C
Citation: U. Sahin et al., INTERLEUKIN-12 INCREASES BISPECIFIC-ANTIBODY-MEDIATED NATURAL-KILLER-CELL CYTOTOXICITY AGAINST HUMAN TUMORS, Cancer immunology and immunotherapy, 42(1), 1996, pp. 9-14
Authors:
PINARD D
OLSSON NO
CHAMBERS WH
MARTIN F
Citation: D. Pinard et al., HIGH EXPRESSION OF NKR-P1 IS NOT AN ABSOLUTE REQUIREMENT FOR NATURAL-KILLER ACTIVITY IN BDIX RATS, Cancer immunology and immunotherapy, 42(1), 1996, pp. 15-23
Authors:
VERVOORDELDONK SF
BALKENENDE AY
VANDENBERG H
VONDEMBORNE AEGK
VANDERSCHOOT CE
VANLEEUWEN EF
SLAPERCORTENBACH ICM
Citation: Sf. Vervoordeldonk et al., DEGRADATION OF RADIOIODINATED B-CELL MONOCLONAL-ANTIBODIES - INHIBITION VIA A FC-GAMMA-RECEPTOR-II-MEDIATED MECHANISM AND BY DRUGS, Cancer immunology and immunotherapy, 42(1), 1996, pp. 24-30
Authors:
OTT MG
MANNEL DN
GALLATI H
GOERIG M
RAETH U
Citation: Mg. Ott et al., PERIPHERAL NATURAL-KILLER-CELL ACTIVITY AND INTRAPERITONEAL SOLUBLE P55 TUMOR-NECROSIS-FACTOR RECEPTOR IN PATIENTS WITH MALIGNANT ASCITES -2 POSSIBLE INDICATORS FOR RESPONSE TO INTRAPERITONEAL COMBINED TUMOR-NECROSIS-FACTOR-ALPHA AND INTERFERON-GAMMA TREATMENT, Cancer immunology and immunotherapy, 42(1), 1996, pp. 31-37